Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience

Table 3 Multiple regression analyses assessing which baseline clinical parameters is associated with a better clinical response to monthly galcanezumab 120 mg administration after 6 months of treatment (dependent variable: headache days/month after 6 months)

Independent variable	Coefficient b	p-value	SE	95% CIs for b Coefficient
Independent variable	Coefficient b	p-value	SE	Lower	Upper
Multiple regression
Disease history (years)	−0.17	0.604	0.08	−0.34	− 0.00
Previous treatments failures	1.85	0.288	1.69	−1.71	5.42
Headache days/month	0.09	0.779	0.32	−0.59	0.77
Headache attacks intensity (NRS)	−3.44	0.026	1.41	−6.42	−0.46
Headache attacks duration (hours)	0.1	0.780	0.35	−0.64	0.83
Whole pain burden	−0.00	0.887	0.00	−0.00	0.00
MIDAS	0.04	0.168	0.03	−0.02	0.10
HIT-6	−0.23	0.443	0.29	−0.84	0.39
MSQ	−0.7	0.375	0.08	−0.23	0.09
PCS	0.39	0.048	0.22	−0.08	0.86
ASC-12	0.29	0.368	0.31	−0.37	0.94
BDI-II	−0.12	0.670	0.28	−0.71	0.47
HDRS	−0.3	0.944	0.35	−0.77	0.72
HARS	0.00	0.987	0.28	−0.58	0.59

Note. SE Standard Error; a, Model F = 1.97, p-value 0.048, R² = 0.62 (Nagelkerke)
NRS numerical rating scale, pts. patients, MIDAS migraine disability assessment scale, HIT-6 headache impact test-6, MSQ migraine-specific quality-of-life questionnaire, BDI II Beck Depression Inventory, HDRS Hamilton Depression Rating Scale, HARS Hamilton Anxiety Rating Scale, PCS Pain Catastrophizing Scale, ASC-12 Allodynia Symptom Checklist-12

ISSN: 1129-2377